Prostate Cancer: Radiopharmaceutical treatment option | Dana-Farber Cancer Institute

Targeting cancer cells with radiopharmaceuticals: patients at Dana-Farber Brigham Cancer Center have a new treatment option for advanced castration-resistant prostate cancer with the recently FDA-approved LuPSMA now in use. Video published 6/30/22